Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03770000 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma
A Phase 1 study, sponsored by Rhizen Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT03770000 is a Phase 1 study that has completed, run by Rhizen Pharmaceuticals. The registered enrollment target is 33 participants.
The verdict
NCT03770000, a Phase 1 study, has completed, sponsored by Rhizen Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) of Tenalisib in combination with Romidepsin in patients with R/R T-cell lymphoma.
Interventions
- DRUG Romidepsin
- DRUG Tenalisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2019-03-12 |
| Est. Completion | 2021-05-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03770000
The ClinicalTrials.gov registry entry for NCT03770000 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rhizen Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Romidepsin is the first listed.
NCT03770000 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03770000 about?
NCT03770000 is a clinical study titled "Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma". To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) of Tenalisib in combination with Romidepsin in patients with R/R T-cell lymphoma.
What is the current status of trial NCT03770000?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2019-03-12. Estimated completion is 2021-05-14.
What interventions are being tested in trial NCT03770000?
The interventions under investigation include: Romidepsin (DRUG), Tenalisib (DRUG).
Who is sponsoring clinical trial NCT03770000?
This trial is sponsored by Rhizen Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.